| Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment (NCT00191555) | Eli Lilly and Company | 2003-08-01 |
| Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia (NCT00155818) | National Taiwan University Hospital | 2003-08-01 |
| As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations (NCT00796185) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-08-01 |
| Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI) (NCT00211380) | Louisiana State University Health Sciences Center Shreveport | 2003-08-01 |
| Evaluation of QTc Interval by Continuous Holter ECG Recording in Antipsychotic Drug-treated Patients With Schizophrenia (NCT00178958) | Northwestern University | 2003-08-01 |
| Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole (NCT00567099) | New Mexico VA Healthcare System | 2003-08-01 |
| Clinical Study Of Schizophrenia in Both Men and Women (NCT00071747) | GlaxoSmithKline | 2003-08-01 |
| Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia (NCT01506765) | Centre Hospitalier Universitaire Vaudois | 2003-08-01 |
| Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia (NCT00073320) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-08-01 |
| Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS) (NCT00211302) | Louisiana State University Health Sciences Center Shreveport | 2003-08-01 |
| Antipsychotic Therapy and First Episode (NCT00334035) | The University of Hong Kong | 2003-08-01 |
| Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus (NCT00222807) | University of Pittsburgh | 2003-08-01 |
| Enhancing the Prospective Prediction of Psychosis (NCT00291200) | Yale University | 2003-08-01 |
| Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia (NCT00073164) | Abbott | 2003-07-01 |
| Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study (NCT00167817) | Veterans Medical Research Foundation | 2003-07-01 |
| A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose (NCT00796029) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-07-01 |
| Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin (NCT00177580) | University of Pittsburgh | 2003-07-01 |
| A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis (NCT00644800) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-07-01 |
| Medication Adherence in Older Adults With Serious Mental Illness (NCT00224380) | Dartmouth-Hitchcock Medical Center | 2003-07-01 |
| A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia (NCT00645515) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-06-01 |
| Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet. (NCT00645502) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-06-01 |
| Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder (NCT00061802) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-06-01 |
| The Effect of a Weight Management Program During Treatment With Olanzapine (NCT00169702) | Heinrich-Heine University, Duesseldorf | 2003-06-01 |
| Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism (NCT00338598) | Yale University | 2003-06-01 |
| Entacapone Augmentation for Schizophrenia (NCT00192855) | Rambam Health Care Campus | 2003-06-01 |
| A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations (NCT00796471) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-06-01 |
| Repetitive Transcranial Magnetic Stimulation (NCT00169689) | Heinrich-Heine University, Duesseldorf | 2003-06-01 |
| Mozart Relapse Study (NCT00143351) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-06-01 |
| The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia (NCT00247637) | University of California, San Diego | 2003-05-01 |
| Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia (NCT00063297) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-05-01 |
| Promoting Adherence to Treatment in Schizophrenia (NCT01125267) | University of California, Los Angeles | 2003-04-01 |
| Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics (NCT00485498) | Eli Lilly and Company | 2003-04-01 |
| Naltrexone Treatment of Alcohol Abuse in Schizophrenia (NCT00145847) | State University of New York - Upstate Medical University | 2003-04-01 |
| Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia. (NCT00239109) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-04-01 |
| Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia (NCT00114595) | University of Stellenbosch | 2003-04-01 |
| Effects of Modafinil on Brain Function in Patients With Schizophrenia (NCT00057707) | National Institute of Mental Health (NIMH) | 2003-03-26 |
| Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials (NCT00239356) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2003-03-01 |
| Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia (NCT00639483) | Pfizer | 2003-03-01 |
| Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia (NCT00197483) | Hamamatsu University | 2003-03-01 |
| A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. (NCT00077727) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-03-01 |
| IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study) (NCT00136994) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-03-01 |
| A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia (NCT00791232) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-03-01 |
| A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone (NCT00796432) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-03-01 |
| Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study (NCT00145444) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-03-01 |
| Risperidone Augmentation in Patients With Schizophrenia (NCT00289861) | Massachusetts General Hospital | 2003-02-01 |
| Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia (NCT00061789) | National Institute of Mental Health (NIMH) | 2003-02-01 |
| Cognitive Remediation and Social Skills Training in Schizophrenia (NCT00223535) | The University of Texas Health Science Center at San Antonio | 2003-02-01 |
| Weight Gain Management in Patients With Schizophrenia (NCT00486005) | Eli Lilly and Company | 2003-02-01 |
| Cognitive Skills Training Using Computer for Patients With Severe Mental Illness (NCT01036282) | Nathan Kline Institute for Psychiatric Research | 2003-02-01 |
| Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia (NCT00546403) | Veterans Medical Research Foundation | 2003-02-01 |
| A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs (NCT00649844) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2003-01-01 |
| Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy (NCT00419653) | University of Jena | 2003-01-01 |
| Shared Decision Making for Schizophrenia (NCT00220870) | Technical University of Munich | 2003-01-01 |
| Treatment of Schizophrenia Through Internet-Based Psychoeducation (NCT00051233) | University of Pittsburgh | 2003-01-01 |
| Serotonin 1A Agonists and Cognition in Schizophrenia (NCT00178971) | Northwestern University | 2003-01-01 |
| The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia (NCT00206947) | Birte Glenthoj | 2002-12-01 |
| Risperidone Maintenance Treatment in Schizophrenia (NCT00848432) | Capital Medical University | 2002-12-01 |
| Ziprasidone in Early Onset Schizophrenia Spectrum Disorders (NCT01006551) | University of North Carolina, Chapel Hill | 2002-12-01 |
| Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia (NCT00401089) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2002-12-01 |
| A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients (NCT00653406) | Janssen Pharmaceutical K.K. | 2002-11-01 |
| Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios (NCT00155506) | National Taiwan University Hospital | 2002-11-01 |
| Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia (NCT00051298) | Eli Lilly and Company | 2002-11-01 |
| Improving Antipsychotic Adherence Among Patients With Serious Mental Illness (NCT00057135) | US Department of Veterans Affairs | 2002-11-01 |
| Screening for Childhood-Onset Psychotic Disorders (NCT00049738) | National Institute of Mental Health (NIMH) | 2002-10-29 |
| A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937) (NCT01101464) | Organon and Co | 2002-10-01 |
| Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis (NCT00628290) | University of Cologne | 2002-10-01 |
| The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study (NCT00206557) | The Alfred | 2002-10-01 |
| Schizophrenia Study In Adults (NCT00049946) | GlaxoSmithKline | 2002-10-01 |
| D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia (NCT00237809) | Yale University | 2002-09-01 |
| Medication Adherence in Older People With Psychosis (NCT00071604) | Veterans Medical Research Foundation | 2002-09-01 |
| Computer Assisted Cognitive Remediation Program in Schizophrenia (NCT01598220) | Gemma Garrido García | 2002-09-01 |
| Safety and Tolerability Study of Drug to Treat Schizophrenia (NCT00044005) | Sumitomo Pharma America, Inc. | 2002-09-01 |
| A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices (NCT00237939) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2002-09-01 |
| A Comparative Study of New Medications for Psychosis in Adolescents (NCT00222495) | University of Minnesota | 2002-08-01 |
| Clinical Trial of Tolcapone for Cognition in Schizophrenia (NCT00044083) | National Institute of Mental Health (NIMH) | 2002-08-01 |
| A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia (NCT00168311) | The Alfred | 2002-08-01 |
| Antipsychotic Medication Extended Dosing Study (NCT00431574) | Centre for Addiction and Mental Health | 2002-08-01 |
| Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia (NCT00155701) | National Taiwan University Hospital | 2002-08-01 |
| Prospective Studies of the Pathogenesis of Schizophrenia (NCT00877552) | University of North Carolina, Chapel Hill | 2002-08-01 |
| Broad Effectiveness: Study With Aripiprazole (NCT00036361) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2002-07-01 |
| Glycine Treatment of Prodromal Symptoms (NCT00268749) | Yale University | 2002-07-01 |
| Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use (NCT00856583) | H. Lundbeck A/S | 2002-07-01 |
| A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia (NCT00044044) | Sumitomo Pharma America, Inc. | 2002-07-01 |
| Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations (NCT00042159) | Yale University | 2002-07-01 |
| A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions (NCT00155519) | National Taiwan University Hospital | 2002-07-01 |
| Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia (NCT00218218) | National Institute on Drug Abuse (NIDA) | 2002-06-01 |
| Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Two State-of-the-Art Interventions (NCT00358709) | University of British Columbia | 2002-06-01 |
| Families Coping With Mental Illness Program (NCT00435721) | North Suffolk Mental Health Association | 2002-06-01 |
| RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice (NCT00458367) | Janssen Pharmaceutica N.V., Belgium | 2002-06-01 |
| Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade (NCT00225498) | Northwell Health | 2002-06-01 |
| Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia (NCT00176423) | University of Maryland, Baltimore | 2002-05-01 |
| Safety and Efficacy of Seroquel in First Episode Schizophrenia (NCT00254241) | AstraZeneca | 2002-05-01 |
| Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder (NCT00236353) | Janssen, LP | 2002-05-01 |
| Treatment of Refractory Schizophrenia With Riluzole (NCT00375050) | Yale University | 2002-05-01 |
| A Positional Cloning Study on Schizophrenia (NCT00155649) | National Taiwan University Hospital | 2002-04-01 |
| Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders (NCT00036127) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2002-04-01 |
| Family Intervention for Mental Illness and Substance Abuse (NCT00043693) | Dartmouth-Hitchcock Medical Center | 2002-04-01 |
| PET Scanning in Parkinson s Disease (NCT00024622) | National Institute of Mental Health (NIMH) | 2002-03-15 |
| CAFE Comparison of Atypicals in First Episode of Psychosis (NCT00034892) | AstraZeneca | 2002-03-01 |
| Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia (NCT00139737) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2002-03-01 |